Antiviral research · 2026
Nanoparticles in viral pneumonia: diagnosis, therapy, and prevention.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Rui, Wang Hailing, Yin Rui, Gemingnuer Ahequeli, Meng Xin
Аннотация
Viral pneumonia, caused by highly transmissible respiratory pathogens including influenza viruses, respiratory syncytial viruses, and coronaviruses, remains a major global health challenge due to its rapid disease progression and high morbidity and mortality. Despite significant advances in antiviral therapies, vaccination strategies, and diagnostic technologies, current clinical interventions are still constrained by low bioavailability, insufficient pulmonary targeting, systemic toxicity, inadequate immunomodulation, and suboptimal early detection. Nanotechnology, as a multidisciplinary approach integrating materials science, immunology, and drug delivery engineering, has been proposed to overcome these limitations. However, comprehensive reviews addressing the fabrication strategies, and therapeutic applications of nanomaterials in viral pneumonia remain limited. This review provides an overview of nanoparticle-based systems, emphasizing rational design principles for pulmonary-targeted therapy and summarizing recent advances in prevention, diagnosis, and treatment. By integrating materials design, biological mechanisms, and translational challenges, it offers a comprehensive framework for interdisciplinary nanotechnology application in viral pneumonia, with strategic directions for lung-targeted delivery, immune modulation, and early diagnosis.